Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Randomized phase II trial of Docetaxel (Taxotere) and Oblimersen vs Docetaxel alone in hormone-refractory prostate cancer
2004-002094-23Phase 2Completed
- Sponsor
- European Organisation for Research and Treatment of Cancer
- Start
- Aug 2004
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial in prostate cancer (PCa) comparing Docetaxel monotherapy with Docetaxel + oblimersen (2 arms). Primary endpoints: PSA response rate and Toxicity. Started Aug 2004; status: completed.
02
Drugs
docetaxeloblimersen
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on 2004-002094-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-002094-23.